CraniSeal Dural Sealant
Pramand, LLC · Decision date Oct 10, 2025
What did the FDA approve?
FDA records P220014/S009 as a supplement to PMA P220014, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Oct 10, 2025.
FDA approval order statement
Approval to move the trilysine acetate from the clear precursor syringe to the diluent syringe.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Oct 10, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P220014/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Pramand, LLC
- Product code
- NQR
- Decision code
- APPR
- Decision date
- Oct 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, dural.
- Applicant
- Pramand, LLC
- Product code
- NQR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220014 · Original PMA
CraniSeal Dural Sealant
P220014/S009 received
Application receipt date recorded by FDA.
P220014/S008 · Related supplement
CraniSeal Dural Sealant
P220014/S009 · FDA decision
Real-Time Process
P220014/S010 · Related supplement
CraniSeal Dural Sealant
P220014/S011 · Related supplement
CraniSeal Dural Sealant
P220014/S012 · Related supplement
CraniSeal Dural Sealant
P220014/S013 · Related supplement
CraniSeal Dural Sealant
Timeline entries are records held by MedtechLedger for P220014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CraniSeal Dural SealantP220014 | Pramand, LLC | PMA approval | Jul 6, 2023 | FDA |
CraniSeal Dural SealantP220014/S008 | Pramand, LLC | PMA supplement | Aug 25, 2025 | FDA |
CraniSeal Dural SealantP220014/S010 | Pramand, LLC | PMA supplement | Jan 16, 2026 | FDA |
CraniSeal Dural SealantP220014/S011 | Pramand, LLC | PMA supplement | Apr 1, 2026 | FDA |
CraniSeal Dural SealantP220014/S012 | Pramand, LLC | PMA supplement | Aug 5, 2026 | FDA |
CraniSeal Dural SealantP220014/S013 | Pramand, LLC | PMA supplement | Oct 1, 2026 | FDA |
Explore the linked device profile
Other records with product code NQR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SpineSeal Spine SealantP240027/S007 | Pramand, LLC | PMA supplement | Sep 11, 2026 | FDA |
SpineSeal Spine SealantP240027/S006 | Pramand, LLC | PMA supplement | Aug 31, 2026 | FDA |
| Stryker Leibinger GmbH & Co. KG | PMA supplement | Jul 15, 2026 | FDA | |
SpineSeal Spine SealantP240027/S005 | Pramand, LLC | PMA supplement | Apr 1, 2026 | FDA |
DuraSeal Dural Sealant SystemP040034/S041 | Integra LifeSciences Corporation | PMA supplement | Feb 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pramand, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., Suite 210, Bedford, MA, 01730
Sources and methodology
- Original FDA record: P220014/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




